Absci Co. (NASDAQ:ABSI – Get Free Report) has been assigned an average recommendation of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports.

“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By ...

“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design ...

“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de ...

“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de ...

Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. Through this strategic partnership, Absci ...

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...

Advanced Micro Devices settled at $121.84 down 4.3%, not far from its 52-week low. AMD has partnered with Absci for AI-driven drug discovery, with CEO Sean McClain set to discuss it on Wednesday at ...

“AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics,” said Absci founder and Chief Executive Officer Sean McClain. Absci will use ...

As part of AMD’s investment in Absci, the company will move toward greater use of AMD’s GPUs, said the company’s founder and Chief Executive Sean McClain. Absci currently uses over 470 AI ...